[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Ji G, Fan JG, Chen JJ, Lu LG, Xing LJ, Zheng PY, Gu HG, Wei HF, You SF, Zhu PT: Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. Zhong Xi Yi Jie He Xue Bao; 2008 Feb;6(2):128-33
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial.
  • OBJECTIVE: To evaluate the efficacy and safety of Danning Tablet (DNT) in patients with non-alcoholic fatty liver disease (NAFLD) of damp-heat syndrome type.
  • METHODS: A multicenter, randomized, double-blinded and positive drug parallel controlled trial was performed.
  • One hundred and thirty-five patients were enrolled into the study and divided into two groups: DNT-treated group (n=102) and ursodeoxycholic acid (UDCA)-treated group (n=33).
  • Body mass index (BMI), principal symptoms, liver function, blood lipids, iconographic, and compositional parameters were measured before and after treatment, respectively.
  • RESULTS: In the two groups, BMI, distress in hepatic region, fatigue, anorexia, liver function, blood lipids and iconographic parameters were significantly improved, and the improvements of BMI, distress in hepatic region were better in DNT-treated group than in UDCA-treated group.
  • The histological study also showed that DNT had positive effect in treatment of NAFLD.
  • CONCLUSION: DNT is an effective drug to treat patients with NAFLD of damp-heat syndrome type and is more effective than UDCA.
  • [MeSH-major] Diagnosis, Differential. Drugs, Chinese Herbal / therapeutic use. Fatty Liver / drug therapy. Medicine, Chinese Traditional. Phytotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241645.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Lipids
  •  go-up   go-down


2. Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Cross JH, Scheper RJ, Harding BN, Thom M: Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia; 2003 Nov;44(11):1388-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy.
  • PURPOSE: The molecular basis of drug resistance in epilepsy is being explored.
  • Two proteins associated with drug resistance in cancer, P-glycoprotein and multidrug resistance-associated protein 1, are upregulated in human epileptogenic pathologies.
  • METHODS: Hippocampal sclerosis (HS), focal cortical dysplasia (FCD), and dysembryoplastic neuroepithelial tumor (DNT) were studied by using immunohistochemistry for MVP and BCRP.
  • Nonepileptogenic control and histologically normal brain adjacent to epileptogenic tissue were used for comparison.
  • Ectopic upregulation of MVP was seen in hilar neurons in HS, dysplastic neurons in FCD, and lesional neurons in DNT.
  • CONCLUSIONS: These results show that more than one resistance protein may be upregulated in a given epileptogenic pathology and may contribute to drug resistance.
  • Determination of the types, amounts, and distribution of such proteins will be necessary for rational treatment for drug resistance in epilepsy.
  • [MeSH-major] Anticonvulsants / adverse effects. Drug Resistance, Multiple / genetics. Epilepsy / drug therapy. Epilepsy / genetics. Vault Ribonucleoprotein Particles / genetics
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / genetics. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Capillaries / pathology. Cerebral Cortex / abnormalities. Cerebral Cortex / pathology. Endothelium, Vascular / pathology. Hippocampus / pathology. Humans. Immunoenzyme Techniques. Neoplasm Proteins / genetics. Neoplasms, Neuroepithelial / genetics. Neoplasms, Neuroepithelial / pathology. Neurons / pathology. Phenotype. Reference Values. Sclerosis. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14636345.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Anticonvulsants; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


3. Mullins CD, Weis KA, Perfetto EM, Subedi PR, Healey PJ: Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. J Manag Care Pharm; 2005 Jun;11(5):394-402
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
  • OBJECTIVE: Managed care and other decision makers need sound comparative information to support the formulary selection process and reimbursement decisions for the treatment of migraine.
  • The objective of this study was to compare currently marketed triptan therapies using number-needed-to-treat (NNT) and doses-needed-to-treat (DNT) measures.
  • DNT was further used to derive triptan treatment cost to achieve 100 successfully treated patients such that the cost-effectiveness of each treatment regime could be compared from the payer perspective.
  • METHODS: Using published meta-analysis data to categorize patients as treatment success or failure, an NNT and a DNT were derived for each triptan.
  • Treatment success was defined as achieving a 2-hour pain response, sustained through 24 hours postdose.
  • Costs were derived by multiplying DNT by the average wholesale price (AWP) minus 15% for each triptan.
  • The highest total triptan cost of treatment was USD 11,136 for naratriptan 2.5 mg.
  • CONCLUSIONS: Eletriptan 40 mg provides the best value in terms of the lowest DNT, assuming an approximately equal AWP discount for each triptan.
  • Future research should further explore the utility of DNT in managed care decision making.
  • [MeSH-major] Migraine Disorders / drug therapy. Serotonin Receptor Agonists / economics. Serotonin Receptor Agonists / therapeutic use
  • [MeSH-minor] Algorithms. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Costs. Humans. Managed Care Programs / economics. Managed Care Programs / statistics & numerical data. Piperidines / administration & dosage. Piperidines / economics. Piperidines / therapeutic use. Pyrrolidines / administration & dosage. Pyrrolidines / economics. Pyrrolidines / therapeutic use. Recurrence. Time Factors. Treatment Outcome. Triazoles / administration & dosage. Triazoles / economics. Triazoles / therapeutic use. Tryptamines / administration & dosage. Tryptamines / economics. Tryptamines / therapeutic use

  • Genetic Alliance. consumer health - Migraine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Manag Care Pharm. 2005 Jun;11(5):419-21 [15934803.001]
  • (PMID = 15934798.001).
  • [ISSN] 1083-4087
  • [Journal-full-title] Journal of managed care pharmacy : JMCP
  • [ISO-abbreviation] J Manag Care Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Piperidines; 0 / Pyrrolidines; 0 / Serotonin Receptor Agonists; 0 / Triazoles; 0 / Tryptamines; 121679-13-8 / naratriptan; 22QOO9B8KI / eletriptan; 51086HBW8G / rizatriptan
  •  go-up   go-down


Advertisement
4. O'Brien DF, Farrell M, Delanty N, Traunecker H, Perrin R, Smyth MD, Park TS, Children's Cancer and Leukaemia Group: The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours. Br J Neurosurg; 2007 Dec;21(6):539-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours.
  • Dysembryoplastic neuroepithelial tumours (DNETs) were incorporated into the new World Health Organization classification of brain tumours as part of the group of glioneuronal tumours in 1993.
  • Large series of patients with DNETs and pharmaco-resistant epilepsy have been reported.
  • DNETs are most often located in the temporal lobe, occurring in both mesial and lateral temporal locations.
  • DNETs have also been reported in the insular cortex, brain stem, cerebellum, occipital lobe and striatum.
  • Approximately 40% of DNETs are cystic, and solitary nodular, multinodular or diffuse forms have been recognized.
  • Approximately 30% of DNETs are associated with subtle cortical dysplastic changes in the adjacent cortex.
  • DNET nodules usually look like oligodendroglioma, whilst between the nodules it may be possible to recognize vertical columns of neurons surrounded by oligodendrocyte-like cells.
  • Cytologically, oligodendroglial-like cells of DNETs are distinguished from oligodendroglioma by larger nuclei with frequent nuclear indentations and multiple, small nucleoli, whilst oligodendrogliomas consistently show nuclear roundness with one or two occasional nucleoli.
  • DNETs are hypodense on CT and demonstrate decreased signal on the T1-weighted images and a hyper-intense signal on T2-weighted MRI.
  • DNETs associated with pharmaco-resistant epilepsy should be removed early to achieve seizure freedom and prevent tumour progression.
  • It is not advocated to use a stereotactic biopsy only, as this may generate an unrepresentative tissue sample consisting of an oligodendroglial component only and may lead to an incorrect diagnosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnostic Imaging / methods. Drug Resistance, Neoplasm / physiology. Epilepsy / diagnosis. Epilepsy / therapy. Female. Humans. Infant. Infant, Newborn. Male. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071981.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


5. Markowska-Woyciechowska A, Zub L, Jarus-Dziedzic K, Rabczyński J, Paradowski B, Budrewicz S, Jabłoński P: [Dysembryoplastic neuroepithelial tumor (DNT)--case report and literature review]. Neurol Neurochir Pol; 2000 Sep-Oct;34(5):1031-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dysembryoplastic neuroepithelial tumor (DNT)--case report and literature review].
  • [Transliterated title] Dysembrioplastyczny nowotwór neuroepitelialny (DNT)--opis przypadku i przeglad piśmiennictwa.
  • Neuroepithelial dysembryoplastic tumour was first described by Daumas-Duport in 1988 and in WHO classification was included into the group of neuronal and mixed neuroglial tumours.
  • This is a benign and very rare tumor with a good prognosis occurring in children and young adults.
  • The tumour caused characteristic clinical symptoms: epileptic fits, supratentorial, intracortical localisation, most often in temporal lobe and specific nodular architecture with heterogenic cell composition.
  • CT examination revealed a tumour in the left parietal lobe.
  • Histological findings showed a typical texture of DNT.
  • The tumour has no tendency for recurrence even in case of incomplete removal and does not require chemotherapy nor radiotherapy which is significantly important for accurate diagnosis, in order to avoid an aggressive therapy in young patients.
  • [MeSH-minor] Adult. Epilepsy / etiology. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11253470.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 20
  •  go-up   go-down


6. Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA: Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood; 2006 Sep 15;108(6):1965-71
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of abnormal lymphocyte survival caused by defective Fas-mediated apoptosis, leading to lymphadenopathy, hepatosplenomegaly, and an increased number of double-negative T cells (DNTs).
  • Treatment options for patients with ALPS are limited.
  • We followed treatment response with serial assessment of DNTs by flow cytometry in blood and lymphoid tissue, by serial monitoring of lymph node and spleen size with ultrasonography, and by enzyme-linked immunosorbent assay (ELISA) for anti-double-stranded DNA (dsDNA) antibodies.
  • Three-dimensional ultrasound measurements in the mice correlated to actual tissue measurements at death (r = .9648).
  • We found a dramatic and statistically significant decrease in DNTs, lymphadenopathy, splenomegaly, and autoantibodies after only 4 weeks when comparing rapamycin-treated mice with controls.
  • We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1993 Dec 15;151(12):7233-9 [7903104.001]
  • [Cites] Cell Immunol. 1993 Apr 15;148(1):91-102 [8495493.001]
  • [Cites] Curr Opin Immunol. 1994 Dec;6(6):913-20 [7536012.001]
  • [Cites] Transplantation. 1998 Jun 15;65(11):1450-4 [9645801.001]
  • [Cites] J Am Soc Nephrol. 1998 Aug;9(8):1407-15 [9697662.001]
  • [Cites] Ann Intern Med. 1999 Apr 6;130(7):591-601 [10189330.001]
  • [Cites] Pediatr Int. 1999 Feb;41(1):104-7 [10200147.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2828-35 [15572590.001]
  • [Cites] Exp Clin Transplant. 2004 Dec;2(2):273-9 [15859941.001]
  • [Cites] Transplant Proc. 2005 Apr;37(3):1509-11 [15866658.001]
  • [Cites] Br J Haematol. 2005 May;129(4):534-8 [15877736.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6337-45 [16024636.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):35829-35 [16109716.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jan;21(1):58-63 [16141461.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2887-92 [12912932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3816-24 [15356129.001]
  • [Cites] Nat Cell Biol. 1999 Jun;1(2):E33-5 [10559890.001]
  • [Cites] Cell Immunol. 1999 Nov 1;197(2):136-44 [10607431.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):3-16 [11135052.001]
  • [Cites] Pediatr Clin North Am. 2000 Dec;47(6):1291-310 [11130997.001]
  • [Cites] Transplant Proc. 2001 May;33(3):2110-1 [11377468.001]
  • [Cites] Clin Immunol. 2001 Sep;100(3):314-24 [11513545.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8 [11583941.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):176-88 [11918552.001]
  • [Cites] Drugs. 2002;62(6):891-907 [11929337.001]
  • [Cites] Clin Exp Immunol. 2002 May;128(2):255-66 [11985515.001]
  • [Cites] Clin Immunol. 2002 Jul;104(1):21-30 [12139944.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4212-6 [12154021.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):227 [2568561.001]
  • [Cites] Science. 1991 Jan 18;251(4991):283-7 [1702904.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 May;16(2):156-9 [8166369.001]
  • (PMID = 16757690.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI051323; United States / NCI NIH HHS / CA / K12 CA 076931-08; United States / NIAID NIH HHS / AI / N01 AI 30070
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; HU9DX48N0T / Mycophenolic Acid; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1895548
  •  go-up   go-down


7. van Tuijn CF, Luitse JS, van der Valk M, van Wissen S, Prins M, Rosmulder R, Geerlings SE: Reduction of the door-to-needle time for administration of antibiotics in patients with a severe infection: a tailored intervention project. Neth J Med; 2010 Mar;68(3):123-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of the door-to-needle time for administration of antibiotics in patients with a severe infection: a tailored intervention project.
  • BACKGROUND: Door-to-needle time (DNT), defined as the time between arrival at the emergency department (ED) and intravenous (iv) antibiotic administration is of crucial importance in the treatment of patients suffering from serious infections.
  • The aim of this project was to reduce the DNT for patients with a serious infection as primary outcome parameter.
  • METHODS: All adult patients arriving at the ED with a suspected infection for whom admission and iv antibiotics were indicated were included.
  • RESULTS: Firstly, baseline DNT was measured and potential delaying factors were identified.
  • Subsequently, five tailored interventions were implemented at regular intervals and their effects on the DNT were analysed.
  • Median baseline DNT was 183 min (IQR 122 to 296).
  • Implementation of the first three interventions did not reduce the DNT ; however, after implementation of the fourth (administer all antibiotics at the ED) and finally all five interventions the DNT was reduced by 15.3% (p=0.040) to a final median DNT of 155 min (IQR 95 to 221).
  • CONCLUSION: Identification of delaying factors and implementation of tailored interventions reduces the DNT .
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Emergency Service, Hospital / organization & administration. Infection / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Length of Stay. Male. Middle Aged. Netherlands. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308707.001).
  • [ISSN] 1872-9061
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


8. Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA: Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood; 2008 Jan 15;111(2):705-14
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with autoimmune lymphoproliferative syndrome (ALPS) and systemic lupus erythematosis (SLE) have T-cell dysregulation and produce abnormal, activated T lymphocytes and an atypical peripheral T-cell population, termed double negative T cells (DNTs).
  • T-cell functions, including DNT transition in T-cell development and T-cell activation, are critically dependent on Notch signaling.
  • We hypothesized that inhibiting Notch signaling would be effective in ALPS and SLE by reducing the production of abnormal DNTs and by blocking aberrant T-cell activation.
  • Mice were randomized to treatment with the notch pathway inhibitor (gamma-secretase inhibitor), N-S-phenyl-glycine-t-butyl ester (DAPT), or vehicle control.
  • Response to treatment was assessed by measurement of DNTs in blood and lymphoid tissue, by monitoring lymph node and spleen size with ultrasound, by quantifying cytokines by bead-array, by ELISA for total IgG and anti-double-stranded DNA (dsDNA) specific antibodies, and by histopathologic assessment for nephritis.
  • Inhibiting the Notch signaling pathway may thus present an effective, novel, and well-tolerated treatment for autoimmune and lymphoproliferative diseases.

  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1813-24 [10601356.001]
  • [Cites] Autoimmunity. 2007 Jun;40(4):299-301 [17516214.001]
  • [Cites] Clin Immunol. 2001 Sep;100(3):314-24 [11513545.001]
  • [Cites] Int Immunol. 2001 Sep;13(9):1155-63 [11526096.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):176-88 [11918552.001]
  • [Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]
  • [Cites] Curr Drug Targets. 2007 Jun;8(6):727-37 [17584028.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1049-55 [17674358.001]
  • [Cites] Expert Opin Ther Targets. 2003 Feb;7(1):35-48 [12556201.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2896-903 [12960312.001]
  • [Cites] Arthritis Rheum. 2003 Sep;48(9):2555-66 [13130475.001]
  • [Cites] Immunity. 2003 Oct;19(4):549-59 [14563319.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):423-31 [15160902.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):4171-8 [15356168.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Immunol. 1989 Jul 1;143(1):103-12 [2525144.001]
  • [Cites] Annu Rev Immunol. 1991;9:243-69 [1910678.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):314-7 [1372394.001]
  • [Cites] J Clin Invest. 1992 Aug;90(2):334-41 [1386609.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1645-56 [1460423.001]
  • [Cites] Cell Immunol. 1993 Apr 15;148(1):91-102 [8495493.001]
  • [Cites] J Immunol. 1993 Dec 15;151(12):7233-9 [7903104.001]
  • [Cites] Int Rev Immunol. 1994;11(3):193-210 [7930845.001]
  • [Cites] Scand J Immunol. 1995 May;41(5):504-8 [7725070.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2871-9 [9108407.001]
  • [Cites] Lupus. 1997;6(3):290-304 [9296771.001]
  • [Cites] Ann Intern Med. 1999 Apr 6;130(7):591-601 [10189330.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2828-35 [15572590.001]
  • [Cites] Br J Haematol. 2005 May;129(4):534-8 [15877736.001]
  • [Cites] Clin Exp Rheumatol. 2005 Mar-Apr;23(2):239-42 [15895897.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Autoimmun Rev. 2005 Jul;4(6):345-50 [16081025.001]
  • [Cites] J Neurosci. 2005 Sep 28;25(39):8898-902 [16192379.001]
  • [Cites] Clin Immunol. 2002 Jul;104(1):21-30 [12139944.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):281-92 [12163557.001]
  • [Cites] Lupus. 2002;11(8):501-7 [12220104.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):535-8 [12406097.001]
  • [Cites] Curr Pharm Des. 2005;11(26):3363-82 [16250842.001]
  • [Cites] Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S120-32 [16273796.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3987-96 [16320345.001]
  • [Cites] J Neuroimmunol. 2005 Dec 30;170(1-2):3-10 [16290267.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):325-35 [16385552.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Cell Immunol. 2006 Feb;239(2):121-8 [16808908.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1965-71 [16757690.001]
  • [Cites] J Exp Med. 2006 Oct 2;203(10):2239-45 [16966428.001]
  • [Cites] Immunity. 2006 Nov;25(5):823-34 [17081781.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43 [16946102.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3612-22 [17075806.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3967-75 [16926289.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):905-18 [17168741.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):552-8 [17099072.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):195-203 [17136549.001]
  • [Cites] Pediatr Clin North Am. 2000 Dec;47(6):1291-310 [11130997.001]
  • (PMID = 17925488.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / PHS HHS / / N01-A1-30 070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Immunoglobulin G; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Receptors, Notch
  • [Other-IDs] NLM/ PMC2200835
  •  go-up   go-down


9. Spalice A, Ruggieri M, Grosso S, Verrotti A, Polizzi A, Magro G, Caltabiano R, Pavone P, Del Balzo F, Platania N, Iannetti P: Dysembryoplastic neuroepithelial tumors: a prospective clinicopathologic and outcome study of 13 children. Pediatr Neurol; 2010 Dec;43(6):395-402
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors: a prospective clinicopathologic and outcome study of 13 children.
  • Dysembryoplastic neuroepithelial tumors (DNETs) are benign intracortical masses that are typically observed in children and young adults and are classified as glioneuronal tumors (WHO grade I).
  • Large and retrospective series of patients with DNETs have been reported, but prospective studies on pediatric cohorts of patients with DNETs have been lacking.
  • The DNETs were located in the frontal (n = 2), temporal (n = 9), or occipital (n = 2) cortex.
  • In 11/13 cases, the seizures were resistant to drug therapy, and all the children had surgery consisting of extended lesionectomy coupled with neuronavigation.
  • This first prospective study with follow-up monitoring of a childhood population with DNETs confirms, on a long-term basis, that the coupled strategy of extended lesionectomy and neuronavigation has good outcome for long-term seizure control.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Cortex / pathology. Neoplasms, Neuroepithelial / pathology. Seizures / pathology
  • [MeSH-minor] Adolescent. Child. Electroencephalography. Female. Humans. Male. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21093729.001).
  • [ISSN] 1873-5150
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. da Silveira RB, Pigozzo RB, Chaim OM, Appel MH, Silva DT, Dreyfuss JL, Toma L, Dietrich CP, Nader HB, Veiga SS, Gremski W: Two novel dermonecrotic toxins LiRecDT4 and LiRecDT5 from brown spider (Loxosceles intermedia) venom: from cloning to functional characterization. Biochimie; 2007 Mar;89(3):289-300
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two novel dermonecrotic toxins LiRecDT4 and LiRecDT5 from brown spider (Loxosceles intermedia) venom: from cloning to functional characterization.
  • The venom contains several toxins, of which the best biochemically and biologically studied is the dermonecrotic toxin, a phospholipase-D.
  • Purified toxin induces cutaneous and systemic loxoscelism, especially necrotic lesions, hematological disturbances and renal failure.
  • Herein, we describe cloning, heterologous expression and purification of two novel dermonecrotic toxins: LiRecDT4 and LiRecDT5.
  • Circular dichroism analysis evidenced correctly folding for toxins but differences in secondary structures.
  • Both proteins were recognized by whole venom serum antibodies and by a specific antibody to dermonecrotic toxin.
  • Also, recombinant toxins with phospholipase activity induced experimental skin lesions and caused a massive inflammatory response in rabbit skin dermis.
  • Nevertheless, toxins displayed different effects upon platelet aggregation, increase in vascular permeability and not caused death in mice.
  • These characteristics in combination with functional studies illustrates that a family of dermonecrotic toxins exists, and includes two novel members that are useful for future structural and functional studies.
  • They will also be useful in biotechnological ends, for example, as inflammatory and platelet aggregating studies, as antigens for serum therapy source and for lipids biochemical research.
  • [MeSH-major] Spider Venoms / genetics. Spider Venoms / metabolism. Spiders / genetics. Toxins, Biological / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Capillary Permeability / drug effects. Circular Dichroism. Cloning, Molecular. DNA, Complementary / chemistry. DNA, Complementary / genetics. Electrophoresis, Polyacrylamide Gel. Mice. Molecular Sequence Data. Phospholipases / genetics. Phospholipases / metabolism. Phylogeny. Platelet Aggregation / drug effects. Rabbits. Recombinant Proteins / chemistry. Recombinant Proteins / metabolism. Recombinant Proteins / toxicity. Sequence Analysis, DNA. Sequence Homology, Amino Acid. Skin / drug effects. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296256.001).
  • [ISSN] 0300-9084
  • [Journal-full-title] Biochimie
  • [ISO-abbreviation] Biochimie
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ431848/ DQ431849
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Recombinant Proteins; 0 / Spider Venoms; 0 / Toxins, Biological; EC 3.1.- / Phospholipases
  •  go-up   go-down


11. Banerjee H, Hawkins Z, Yakubu M, Smoot D, Asktorab M, Dutta SK: 2Am-DNT induces cell death and apoptosis in human cells. J Environ Pathol Toxicol Oncol; 2009;28(3):231-4
Hazardous Substances Data Bank. Trypan blue .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2Am-DNT induces cell death and apoptosis in human cells.
  • During microbial or mammalian cell metabolism, TNT (2,4,6-tinitrotoluene) is reduced to 2Am-DNT (2-amino-4,6-dinitrotoluene), 4Am-DNT, or 2,4-diamino-NT (2,4-diaminonitrotoluelne) depending on the specific organism.
  • The metabolite 2Am-DNT is the most common of the TBT biotransformation pathways in bacterial and fungal species studied to date. in the mammalian liver cells, TNT is metabolized to 2Am-DNT by the P450 enzyme system.
  • Apoptosis is rapidly emerging as a relevant endpoint for detecting low-dose toxin exposure.
  • We report in this study that 2Am-DNT treatment of mammalian cells causes cell death by apoptosis.
  • Apoptotic changes, such as DNA break down, were detected in treated cells by the production of a dark-brown DAB (diaminobenzidine) signal using the Fragel Klenow DNA fragment detection system, by immunohistochemical techniques with fluorescence microscopy, and by using a microplate reader for a single-stranded DNA binding assay.
  • All of these results showed that 2am-DNT is toxic to mammalian cells and induces apoptosis.
  • [MeSH-major] Aniline Compounds / toxicity. Apoptosis / drug effects. Environmental Pollutants / toxicity
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. Cell Survival / drug effects. DNA Damage. DNA, Single-Stranded / drug effects. DNA, Single-Stranded / metabolism. Female. Humans. In Situ Nick-End Labeling. Microscopy, Fluorescence. Trypan Blue / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888910.001).
  • [ISSN] 2162-6537
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / DNA, Single-Stranded; 0 / Environmental Pollutants; 189OOM840S / 2-amino-4,6-dinitrotoluene; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


12. Muqueet MA, Sirajul Haque KM, Faruque GM, Hossain M, Khan RJ, Mahmood M, Ounpuu S, Yusuf S: An evaluation of door to needle time (DNT) of thrombolytic therapy following acute myocardial infarction in three large tertiary referral hospitals in Dhaka City. Bangladesh Med Res Counc Bull; 2006 Apr;32(1):29-34
MedlinePlus Health Information. consumer health - Heart Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of door to needle time (DNT) of thrombolytic therapy following acute myocardial infarction in three large tertiary referral hospitals in Dhaka City.
  • Secondary data was obtained from the standard questionnaires to determine door to needle time (DNT) following thrombolytic therapy in patients with Acute Myocardial Infarction (AMI) in coronary care units at three large tertiary referral hospitals in Dhaka city.
  • Of total 192 patients studied in three centres, 156 (81.2%) received thrombolytic therapy.
  • Mean DNT was 147 minutes.
  • Mean DNT was 210 minutes.
  • Sixty seven (82%) patients received therapy within 90 minutes, 6 patients (9%) received between thrombolysis 91-180 minutes and 6 (9%) patients received after 180 minutes of reaching hospital.
  • In this study, the mean DNT for thrombolysis was quickest (64 minutes) at NICVD and slowest (210 minutes) at DMCH.
  • [MeSH-major] Efficiency, Organizational. Emergency Service, Hospital. Myocardial Infarction / drug therapy. Thrombolytic Therapy
  • [MeSH-minor] Acute Disease. Bangladesh. Humans. Prospective Studies. Surveys and Questionnaires. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665831.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


13. Rushing EJ, Thompson LD, Mena H: Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. Ann Diagn Pathol; 2003 Aug;7(4):240-4
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
  • We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy.
  • The subtotally excised superficial right temporoparietal tumor was originally diagnosed as mixed oligoastrocytoma in 1974; the patient was treated with radiation therapy postoperatively.
  • One year later he underwent a craniotomy to remove cyst fluid and no change was reported in the size of the residual tumor.
  • Postoperatively, he received a 6-week course of chemotherapy (lovustine, CCNU).
  • He remained clinically and radiographically stable until 3 years later, when seizure activity returned and imaging studies were consistent with tumor recurrence.
  • Review of the initial biopsy showed cortical fragments containing abundant calcifications and multinodular structures typical of the complex form of DNT, in addition to specific glioneuronal elements.
  • The specimen from the third surgery showed an anaplastic astrocytoma (Ki-67 up to 12%) and morphologic features characteristic of radiation effect.
  • This is the first documented case of malignant transformation of DNT following radiation and adjuvant chemotherapy.
  • The implications of malignant transformation in subtotally excised complex DNTs and the intriguing issue of the contribution of radiation/chemotherapy are discussed.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Craniotomy. Fatal Outcome. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Lomustine / therapeutic use. Male

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12913847.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


14. Slotkin TA, Oliver CA, Seidler FJ: Critical periods for the role of oxidative stress in the developmental neurotoxicity of chlorpyrifos and terbutaline, alone or in combination. Brain Res Dev Brain Res; 2005 Jun 30;157(2):172-80
Hazardous Substances Data Bank. CHLORPYRIFOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical periods for the role of oxidative stress in the developmental neurotoxicity of chlorpyrifos and terbutaline, alone or in combination.
  • The developmental neurotoxicity of chlorpyrifos (CPF) involves mechanisms other than inhibition of cholinesterase.
  • These results indicate that diverse compounds can exert convergent effects on brain development through their shared potential to elicit oxidative stress, and that the net outcome is dependent upon specific developmental stages in which metabolic demand is especially high.
  • Furthermore, given the common use of terbutaline in the therapy of preterm labor, and the nearly ubiquitous exposure of the human population to organophosphorus pesticides, the combined oxidative burden of exposure to both agents may contribute to the worsened neurodevelopmental outcomes noted in animal models of such dual exposures.
  • [MeSH-major] Brain / drug effects. Brain Damage, Chronic / chemically induced. Chlorpyrifos / toxicity. Neurotoxins / toxicity. Oxidative Stress / drug effects. Prenatal Exposure Delayed Effects. Terbutaline / toxicity
  • [MeSH-minor] Adrenergic beta-Agonists / toxicity. Age Factors. Animals. Animals, Newborn. Cell Death / drug effects. Cell Death / physiology. Cell Differentiation / drug effects. Cell Differentiation / physiology. Cholinesterase Inhibitors / toxicity. Critical Period (Psychology). Disease Models, Animal. Dose-Response Relationship, Drug. Drug Synergism. Female. Lipid Peroxidation / drug effects. Lipid Peroxidation / physiology. Nerve Degeneration / chemically induced. Nerve Degeneration / metabolism. Nerve Degeneration / physiopathology. Pregnancy. Rats. Rats, Sprague-Dawley. Thiobarbituric Acid Reactive Substances / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963356.001).
  • [ISSN] 0165-3806
  • [Journal-full-title] Brain research. Developmental brain research
  • [ISO-abbreviation] Brain Res. Dev. Brain Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES10356; United States / NIEHS NIH HHS / ES / ES10387; United States / NICHD NIH HHS / HD / HD09713
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Cholinesterase Inhibitors; 0 / Neurotoxins; 0 / Thiobarbituric Acid Reactive Substances; JCS58I644W / Chlorpyrifos; N8ONU3L3PG / Terbutaline
  •  go-up   go-down


15. Hammond RR, Duggal N, Woulfe JM, Girvin JP: Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2000 Apr;92(4):722-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report.
  • A 29-year-old man presented in 1984 with a recent onset of partial seizures marked by speech arrest.
  • Computerized tomography (CT) scanning revealed a superficial hypodense nonenhancing lesion in the midleft frontal convexity, with some remodeling of the overlying skull.
  • He received no chemotherapy or radiation therapy and remained well for 11 years.
  • A Grade IV astrocytoma was resected, and within the malignant tumor was a superficial area reminiscent of a dysembryoplastic neuroepithelial tumor (DNT).
  • Data on the lesion that had been resected in 1984 were reviewed, and in retrospect the lesion was identified as a DNT of the complex form.
  • This case is the first documented example of malignant transformation of a DNT.
  • This warning may be especially warranted when confronted with complex forms of DNT.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Electroencephalography. Epilepsies, Partial / diagnosis. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / pathology. Neuroglia / pathology. Neurons / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761668.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Altinörs N, Calisaneller T, Gülşen S, Ozen O, Ongürü O: Intraventricular dysembryoplastic neuroepithelial tumor: case report. Neurosurgery; 2007 Dec;61(6):E1332-3; discussion E1333
Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular dysembryoplastic neuroepithelial tumor: case report.
  • OBJECTIVE: The most common localization of dysembryoplastic neuroepithelial tumors (DNTs) is the supratentorial cortex, often in the temporal lobe.
  • However, intraventricular localization of a DNT is extremely rare.
  • CLINICAL PRESENTATION: A 30-year-old woman presented with a 1-year history of epileptic seizures.
  • Based on histopathological and immunohistochemical evaluation, a DNT was diagnosed.
  • The most recent neuroimaging examinations revealed neither residual nor recurrent tumor.
  • CONCLUSION: Because DNTs are surgically curable and neither radiotherapy nor chemotherapy is required after surgery, recognition of an intraventricular DNT in this location is extremely important.
  • [MeSH-major] Cerebral Ventricle Neoplasms. Lateral Ventricles / pathology. Neoplasms, Neuroepithelial

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162864.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


17. Chen L, Xu QZ, Piao YS, Zhang GJ, Yu T, Yang XP, Yang H, Lu DH: [Dysembryoplastic neuroepithelial tumor: a clinicopathologic and immunohistochemical study]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):524-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dysembryoplastic neuroepithelial tumor: a clinicopathologic and immunohistochemical study].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and histogenesis of dysembryoplastic neuroepithelial tumor (DNT).
  • METHODS: Fourteen cases of DNT were retrieved from the archival files of the Department.
  • Histologically, the tumor consisted of a heterogeneous admixture of neuronal and glial cells (including 1 simple form case, 8 complex form cases and 5 non-specific form cases).
  • Variable degrees of cortical dysplasia (CD) were found in 10 out of the 11 cases which had sufficient tissue samples for thorough histologic examination.
  • The morphologic appearance of CD included the presence of heterotopic neurons in molecular layer and/or white matter (7 cases), persistent subpial granular cell layer (4 cases), dyslamination (10 cases) and cellular abnormalities.
  • No tumor recurrence was detected.
  • CONCLUSIONS: DNT is frequently associated with CD.
  • The morphologic diagnosis can be confirmed by immunohistochemical study using a panel of antibodies.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Brain Neoplasms / pathology. Malformations of Cortical Development / pathology. Neoplasms, Neuroepithelial / pathology. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Child. Child, Preschool. Epilepsy / drug therapy. Epilepsy / etiology. Female. Follow-Up Studies. Humans. Infant. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Nestin. Oligodendroglia / pathology. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980099.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Intermediate Filament Proteins; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human
  •  go-up   go-down


18. Tatke M, Suri VS, Malhotra V, Sharma A, Sinha S, Kumar S: Dysembryoplastic neuroepithelial tumors: report of 10 cases from a center where epilepsy surgery is not done. Pathol Res Pract; 2001;197(11):769-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors: report of 10 cases from a center where epilepsy surgery is not done.
  • Dysembryoplastic neuroepithelial tumor (DNT) is a recently recognized tumor entity with distinctive clinicopathological features and an excellent long-term prognosis.
  • We report 10 cases of DNT out of neurosurgical specimens sent for histopathological examination since 1994.
  • Epilepsy surgery is not done at our center, and all the cases were sent with a clinical diagnosis of glioma.
  • This study therefore reports 4 cases of simple DNT and 6 cases of complex DNT.
  • It is very important to recognize this entity, as surgery cures the patient, and radiotherapy or chemotherapy is not required.
  • [MeSH-major] Brain Neoplasms / pathology. Epilepsies, Partial / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Proteins / analysis. Prospective Studies. Tomography, X-Ray Computed


19. Baisden BL, Brat DJ, Melhem ER, Rosenblum MK, King AP, Burger PC: Dysembryoplastic neuroepithelial tumor-like neoplasm of the septum pellucidum: a lesion often misdiagnosed as glioma: report of 10 cases. Am J Surg Pathol; 2001 Apr;25(4):494-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumor-like neoplasm of the septum pellucidum: a lesion often misdiagnosed as glioma: report of 10 cases.
  • The authors report a series of 10 low-grade neoplasms arising in the midline anteriorly in the region of the septum pellucidum with many of the histologic features of dysembryoplastic neuroepithelial tumor (DNT).
  • The tumors, in aggregate, had the histologic features of DNT.
  • No patients received adjuvant chemotherapy or radiotherapy.
  • On the basis of both neuroimaging and histopathology, DNT-like lesions should be considered in the differential diagnosis of midline intraventricular tumors in children and young adults.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Proteins / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11257624.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • She then underwent radiation therapy.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • Although the histological findings of the first surgical specimen closely resembled those of DNT, radiologic findings and clinical course were different from those of DNT.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Ji G, Fan JG, Chen JJ: [Clinical study on treatment of non-alcoholic fatty liver of damp-heat syndrome type by danning tablet]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jun;25(6):485-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of non-alcoholic fatty liver of damp-heat syndrome type by danning tablet].
  • OBJECTIVE: To evaluate the therapeutic effect of Danning Tablet (DNT) on patients with non-alcoholic fatty liver (NAFL) of damp-heat Syndrome type.
  • One hundred and two patients were treated with DNT and 33 patients treated with Ursodeoxycholic acid (UDCA) as control.
  • Indexes including body mass index (MBI), principal symptom, liver function, blood lipids, iconographic parameters and comprehensive efficacy were measured before and after treatment in the two groups respectively.
  • RESULTS: DNT and UDCA had the effect in improving BMI, distress in hepatic region, fatigue, anorexia, liver function, blood lipids and iconographic parameters, etc.
  • DNT showed effects in improving BMI and distress in hepatic region better than those of UDCA.
  • Histological examination also showed that DNT had good therapeutic effect.
  • CONCLUSION: DNT is an effective medicine for NAFL patients of damp-heat Syndrome type, and its efficacy is better than that of UDCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025957.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Tablets
  •  go-up   go-down


22. Daumas-Duport C, Varlet P: [Dysembryoplastic neuroepithelial tumors]. Rev Neurol (Paris); 2003 Jul;159(6-7 Pt 1):622-36
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dysembryoplastic neuroepithelial tumors].
  • Dysembryoplastic neuroepithelial tumors DNTs are highly polymorphic tumors that arise during embryogenesis.
  • Their differential diagnosis from gliomas is obviously important to spare these young patients with a normal life expectancy the long- term deleterious effect of radiation or chemotherapy.
  • The diagnosis of DNT must be considered when all the following criteria are present: partial seizures with or without secondary generalization, no neurological deficit or a stable congenital deficit, cortical topography on MRI, absence of peri-tumoral edema and of mass effect.
  • In other locations, the diagnosis of DNT has to be suspected in case of discordance between the neurological status of the patient and the topography of the tumor or of unusual radiological features such as contrast enhancement but no mass effect and no edema.
  • Supratentorial cortical DNTs tend now to be detected more systematically by imaging soon after first seizures.
  • DNTs should therefore be operated soon after diagnosis.
  • However, excellent results can also be obtained by epilepsy surgery in patients with long term drug resistant partial seizures.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Neuroepithelial / pathology. Temporal Lobe / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910070.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


23. Rubio E, Moreno JM, Turrión VS, Jimenez M, Lucena JL, Cuervas-Mons V: De novo malignancies and liver transplantation. Transplant Proc; 2003 Aug;35(5):1896-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: De novo tumors (DNTs) are the leading cause of late death among liver transplant recipients with an incidence of 5% to 15%, which is significantly greater than the general population.
  • PATIENTS: Among 410 patients who received liver allografts between March 1986 and December 2000, 32 (7.8%) developed a DNT.
  • Treatment consisted of surgery in 76.7%, radiotherapy in 16.7%, chemotherapy in 13.3%, and reduction of immunosuppression in 10%.
  • RESULTS: The mean survival time in transplant patients of 122.97 months (95% CI; range 98-147 months) was significantly shorter than controls, 156.5 months (95% CI; range 141-171 months).
  • CONCLUSIONS: DNTs, a complication of long-term immunosuppression in patients after liver transplantation, most frequently presented as skin tumors and PTLD.
  • Occurrence of a DNT was an adverse prognostic factor for survival.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cause of Death. Follow-Up Studies. Humans. Middle Aged. Postoperative Complications / mortality. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12962838.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Brüning T, Thier R, Mann H, Melzer H, Bröde P, Dallner G, Bolt HM: Pathological excretion patterns of urinary proteins in miners highly exposed to dinitrotoluene. J Occup Environ Med; 2001 Jul;43(7):610-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cohort of 161 underground miners who had been highly exposed to dinitrotoluene (DNT) in the copper-mining industry of the former German Democratic Republic was reinvestigated for signs of subclinical renal damage.
  • The study included a screening of urinary proteins excreted by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and quantitations of the specific urinary proteins alpha 1-microglobulin and glutathione-S-transferase alpha (GST alpha) as biomarkers for damage of the proximal tubule and glutathione-S-transferase pi (GST pi) for damage of the distal tubule.
  • The exposures were categorized semiquantitatively (low, medium, high, and very high), according to the type and duration of professional contact with DNT.
  • A straight dose-dependence of pathological protein excretion patterns with the semiquantitative ranking of DNT exposure was seen.
  • The damage from DNT was directed toward the tubular system.
  • Data on the biomarkers alpha 1-microglobulin, GST alpha, and GST pi consistently demonstrated a dose-dependent increase in tubular damage, which confirmed the results of screening by SDS-PAGE and clearly indicated a nephrotoxic effect of DNT under the given conditions of exposure.
  • Within the cluster of cancer patients observed among the DNT-exposed workers, only in exceptional cases were normal biomarker excretions found.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464391.001).
  • [ISSN] 1076-2752
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dinitrobenzenes; 0 / Isoenzymes; 0 / Membrane Glycoproteins; 0 / SPINT2 protein, human; 9088-41-9 / Trypsin Inhibitor, Kunitz Soybean; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha
  •  go-up   go-down


25. Aslan A, Cemek M, Buyukokuroglu ME, Altunbas K, Bas O, Yurumez Y, Cosar M: Dantrolene can reduce secondary damage after spinal cord injury. Eur Spine J; 2009 Oct;18(10):1442-51
Hazardous Substances Data Bank. DANTROLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-four New Zealand rabbits were divided into three groups: Sham (no drug or operation, n = 8), Control (SCI + 1 mL saline intraperitoneally (i.p.
  • ), n = 8), and DNT (SCI + 10 mg/kg dantrolene in 1 mL, i.p., n = 8).
  • Blood, cerebrospinal fluid and tissue sample from spinal cord were taken for measurements of antioxidant status or detection of apoptosis.
  • After 4 h SCI, all animals in control or DNT-treated groups became paraparesic.
  • Significant improvement was observed in DNT-treated group, 24 h after SCI, with respect to control.
  • DNT treatment prevented lipid peroxidation and augmented endogenous enzymic or non-enzymic antioxidative defense systems.
  • Again, DNT treatment significantly decreased the apoptotic cell number induced by SCI.
  • In conclusion, experimental results observed in this study suggest that treatment with dantrolene possess potential benefits for traumatic SCI.
  • [MeSH-major] Dantrolene / pharmacology. Nerve Degeneration / drug therapy. Oxidative Stress / drug effects. Spinal Cord Injuries / drug therapy
  • [MeSH-minor] Animals. Antioxidants / metabolism. Apoptosis / drug effects. Apoptosis / physiology. Cell Count. Disease Models, Animal. Disease Progression. Female. Lipid Peroxidation / drug effects. Lipid Peroxidation / physiology. Male. Muscle Relaxants, Central / pharmacology. Muscle Relaxants, Central / therapeutic use. Neurons / drug effects. Neurons / metabolism. Neuroprotective Agents / pharmacology. Neuroprotective Agents / therapeutic use. Rabbits. Spinal Cord / drug effects. Spinal Cord / metabolism. Spinal Cord / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1995 Aug 14;370(1-2):37-40 [7649301.001]
  • [Cites] Pharmacol Res. 2001 Dec;44(6):491-4 [11735355.001]
  • [Cites] Annu Rev Nutr. 1996;16:33-50 [8839918.001]
  • [Cites] Brain Res. 1997 Aug 15;765(2):283-90 [9313901.001]
  • [Cites] J Lab Clin Med. 1963 May;61:882-8 [13967893.001]
  • [Cites] Toxicol In Vitro. 2005 Aug;19(5):589-94 [15896552.001]
  • [Cites] Magnes Res. 2005 Sep;18(3):170-4 [16259377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16379-84 [16260722.001]
  • [Cites] Hum Exp Toxicol. 2006 Mar;25(3):127-33 [16634331.001]
  • [Cites] J Surg Res. 2006 Jun 15;133(2):159-66 [16337967.001]
  • [Cites] Int J Dev Neurosci. 2006 Jun;24(4):233-9 [16701976.001]
  • [Cites] Histol Histopathol. 2006 Oct;21(10):1091-102 [16835831.001]
  • [Cites] J Pineal Res. 2006 Sep;41(2):142-9 [16879320.001]
  • [Cites] Acta Pharmacol Sin. 2006 Oct;27(10):1317-25 [17007738.001]
  • [Cites] Chin J Traumatol. 2006 Oct;9(5):303-7 [17026864.001]
  • [Cites] Ann Acad Med Singapore. 2007 Jan;36(1):49-57 [17285186.001]
  • [Cites] J Neurosci. 2007 Apr 11;27(15):4154-64 [17428993.001]
  • [Cites] J Clin Neurosci. 2007 Jul;14(7):658-65 [17532502.001]
  • [Cites] Biomaterials. 2008 Apr;29(12):1967-75 [18255138.001]
  • [Cites] J Pineal Res. 2008 May;44(4):348-57 [18086148.001]
  • [Cites] CNS Drugs. 2008;22(6):455-75 [18484790.001]
  • [Cites] Eur Spine J. 2008 Jun;17(6):864-72 [18351400.001]
  • [Cites] Injury. 2008 Jul;39(7):748-52 [18541241.001]
  • [Cites] Thorac Cardiovasc Surg. 2008 Oct;56(7):406-11 [18810698.001]
  • [Cites] Eur Spine J. 2009 Mar;18(3):336-44 [19130093.001]
  • [Cites] Curr Opin Neurol. 2002 Jun;15(3):355-60 [12045737.001]
  • [Cites] Pharmacol Res. 2002 Jun;45(6):455-60 [12162945.001]
  • [Cites] J Pineal Res. 2003 Apr;34(3):173-7 [12614476.001]
  • [Cites] Cell Biochem Funct. 2003 Jun;21(2):127-31 [12736901.001]
  • [Cites] Spinal Cord. 2003 Jul;41(7):369-78 [12815368.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Annu Rev Biochem. 1983;52:711-60 [6137189.001]
  • [Cites] Methods Enzymol. 1984;105:121-6 [6727660.001]
  • [Cites] Methods Enzymol. 1984;105:93-104 [6328209.001]
  • [Cites] Diabetes. 1989 Dec;38(12):1539-43 [2583378.001]
  • [Cites] Nihon Juigaku Zasshi. 1990 Dec;52(6):1281-3 [2287135.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):15-26 [2045903.001]
  • [Cites] Biochim Biophys Acta. 1992 Oct 13;1180(1):73-82 [1327163.001]
  • [Cites] Ann Emerg Med. 1993 Jun;22(6):1022-7 [8503522.001]
  • [Cites] Ann Emerg Med. 1993 Jun;22(6):987-92 [8503537.001]
  • [Cites] Tokushima J Exp Med. 1994 Dec;41(3-4):133-6 [7701506.001]
  • [Cites] J Pineal Res. 2000 Oct;29(3):184-92 [11034116.001]
  • [Cites] Nitric Oxide. 2001 Feb;5(1):62-71 [11178938.001]
  • [Cites] Gen Pharmacol. 1996 Apr;27(3):513-7 [8723536.001]
  • (PMID = 19468761.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Muscle Relaxants, Central; 0 / Neuroprotective Agents; F64QU97QCR / Dantrolene
  • [Other-IDs] NLM/ PMC2899378
  •  go-up   go-down


26. Engelhard HH, Stelea A, Cochran EJ: Oligodendroglioma: pathology and molecular biology. Surg Neurol; 2002 Aug;58(2):111-7; discussion 117
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: On histologic examination, oligodendrogliomas must be differentiated from tumors including the fibrillary astrocytoma, clear cell ependymoma, central neurocytoma, and dysembryoplastic neuroepithelial tumor (DNT).
  • There is no specific immunocytochemical marker allowing for the recognition of human oligodendroglial tumor cells.
  • New molecular and genetic markers may aid in grading oligodendrogliomas and identifying patients with a better prognosis or response to chemotherapy.
  • The combination of allelic losses on chromosomes 1p and 19q has been statistically associated with a longer recurrence-free survival after chemotherapy.
  • CONCLUSIONS: A patient with an oligodendroglioma may at times still present a diagnostic challenge for the neuropathologist.
  • Yet making an accurate diagnosis is essential, since the clinical course and optimal therapeutic approach differs from that of other gliomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology


27. Xu F, Prescott MF, Liu PX, Chen ZH, Liau G, Gordon EM, Hall FL: Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med; 2001 Jul;8(1):19-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, there is no known therapeutic strategy that has been sufficiently effective to warrant its widespread use.
  • In the present study, the anti-proliferative properties of a matrix (collagen)-targeted retroviral vector bearing a mutant cyclin G1 (DNT 41-249) construct was evaluated in vitro and in vivo.
  • [MeSH-minor] 3T3 Cells. Amino Acid Sequence. Angioplasty, Balloon / adverse effects. Animals. Carotid Arteries / chemistry. Carotid Arteries / pathology. Cell Division / drug effects. Cell Division / genetics. Cell Line. Cyclin G. Cyclin G1. DNA, Antisense / genetics. DNA, Recombinant / genetics. Gene Transfer Techniques. Genetic Therapy / methods. Genetic Vectors / administration & dosage. Humans. Immunohistochemistry. Mice. Molecular Sequence Data. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / metabolism. Mutation. Rats. Retroviridae / genetics. Sequence Homology, Amino Acid. Time Factors. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408944.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCNG1 protein, human; 0 / Ccng1 protein, mouse; 0 / Ccng1 protein, rat; 0 / Cyclin G; 0 / Cyclin G1; 0 / Cyclins; 0 / DNA, Antisense; 0 / DNA, Recombinant
  •  go-up   go-down


28. Slonim AE, Grovit M, Bulone L: Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J Am Coll Nutr; 2009 Jun;28(3):277-85
Hazardous Substances Data Bank. CURCUMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease.
  • Anti-inflammatory, immunomodulatory, and monoclonal antibody drugs, as well as growth hormone (GH), frequently fail to achieve sustained remission or reverse growth failure.
  • OBJECTIVE: To test whether an exclusion diet with nutraceutical therapy (DNT) could induce sustained clinical remission and weight gain, and if so does this enhance the ability for GH to reverse growth failure.
  • All were treated with DNT.
  • RESULTS: Within 2 months of starting DNT all six patients went into remission, with discontinuation of all pharmacological drugs.
  • One patient with very severe CD had recurrence of CD symptoms after being in complete remission for 18 months, one patient was in remission for 3 years but symptoms recurred when she became less compliant to DNT and one recently treated patient remains in remission after 6 months.
  • With the addition of rhGH, the 4 growing patients had good-excellent growth response CONCLUSION: DNT engendered prolonged remission and restoration of normal weight in moderate-severe juvenile CD patients, providing conditions that enabled rhGH to stimulate growth.
  • These findings justify larger controlled trials to evaluate the long-term benefit of compliance to DNT in both juvenile and adult CD patients.
  • [MeSH-major] Crohn Disease / diet therapy. Dietary Supplements. Growth Disorders / therapy. Human Growth Hormone / therapeutic use. Micronutrients / therapeutic use
  • [MeSH-minor] Adolescent. Amino Acids / therapeutic use. Animals. Boswellia. Cattle. Colostrum. Combined Modality Therapy. Curcuma. Curcumin / therapeutic use. Female. Fishes. Growth / drug effects. Humans. Lactobacillus. Male. Peptides / therapeutic use. Plant Extracts / therapeutic use. Probiotics / therapeutic use. Prospective Studies. Young Adult


29. Mirzaee S, Eriksson S, Albertioni F: Differences in cytosolic and mitochondrial 5'-nucleotidase and deoxynucleoside kinase activities in Sprague-Dawley rat and CD-1 mouse tissues: implication for the toxicity of nucleoside analogs in animal models. Toxicology; 2010 Jan 12;267(1-3):159-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in cytosolic and mitochondrial 5'-nucleotidase and deoxynucleoside kinase activities in Sprague-Dawley rat and CD-1 mouse tissues: implication for the toxicity of nucleoside analogs in animal models.
  • Cytosolic and mitochondrial deoxynucleoside kinases (dNKs), as well as 5'deoxynucleotidases (5'-dNTs), control intracellular and intramitochondrial phosphorylation of natural nucleotides and nucleoside analogs used in antiviral and cancer chemotherapy.
  • The balance in the activities of these two groups of enzymes to a large extent determines both the efficacy and side effects of these drugs.
  • Because of the broad and overlapping substrate specificities of the nucleoside kinases and 5'-NTs, their tissue distribution and roles in the metabolism of both natural nucleosides and their analogs are still not fully elucidated.
  • Here, the activity of dNKs: dCK and TK (TK1 and TK2) as well as 5'-dNTs: CN1, CN2 and dNT (dNT1 and dNT2) were determined in 14 different adult mouse and rat tissues.
  • In most cases tissue activities of TK1, TK2 and dCK were 2-3-fold higher in the mouse, a similar pattern was found with CN1 and dNTs although with several exceptions, e.g., TK2 activities in muscle extracts from rats were 2-10-fold higher than in the mouse.
  • CN2 had higher levels in the testis, spleen, pancreas and diaphragm and lower level in the lung of mouse compared to rat tissues.
  • The result suggests that a major difference in these activity profiles between mouse and rat may account for discrepancies in pharmacological response of the two animals to certain nucleoside compounds, and may help to improve the usefulness of animal models in future efforts of drug discovery.
  • [MeSH-minor] Adipose Tissue / enzymology. Animals. Kidney / enzymology. Liver / enzymology. Male. Mice. Models, Animal. Rats. Rats, Sprague-Dawley. Thymidine Kinase / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19913594.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Nucleosides; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / deoxyribonucleoside kinases; EC 2.7.1.21 / Thymidine Kinase; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


30. Galldiks N, Zaro-Weber O, Dohmen C, Neveling M, Haupt WF, Fink GR, Sobesky J: Systemic thrombolysis with rt-PA in patients under 40 years of age: a subgroup analysis of the Cologne Stroke Experience. Cerebrovasc Dis; 2010;30(5):514-8
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: While the application of intravenous systemic thrombolysis (IVT) with rt-PA (recombinant tissue plasminogen activator) in older patients is currently moving into the focus of epidemiological studies, only few data are available regarding the application in young patients ≤40 years.
  • Single-center data of a thrombolysis register were analyzed with respect to safety and efficacy of the treatment of young patients.
  • METHODS: In a retrospective subgroup analysis of 450 patients treated by IVT within a 3-hour time window, patients ≤40 years were identified (n = 20).
  • Clinical data [age, pretherapeutic stroke severity (National Institute of Health Stroke Scale, NIHSS), OTT (onset to-treatment time), rt-PA-dose, DNT (door[-]to[-]needle time), rate of symptomatic intracranial hemorrhages] and medical history were determined.
  • In comparison to patients >40 years, OTT, DNT and NIHSS at admission were not significantly different.
  • [MeSH-major] Fibrinolytic Agents / therapeutic use. Stroke / drug therapy. Thrombolytic Therapy / methods. Tissue Plasminogen Activator / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Cohort Studies. Female. Germany. Humans. Injections, Intravenous. Male. Retrospective Studies. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20861623.001).
  • [ISSN] 1421-9786
  • [Journal-full-title] Cerebrovascular diseases (Basel, Switzerland)
  • [ISO-abbreviation] Cerebrovasc. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


31. Azevedo LL, Cardoso F, Reis C: [Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa]. Arq Neuropsiquiatr; 2003 Dec;61(4):995-8
MedlinePlus Health Information. consumer health - Speech and Communication Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of dopaminergic systems in the pathogenesis of these changes as well as the therapeutic effect of L-dopa have not been clearly determined.
  • Duration of the statement (D), duration of the PNT (DPNT), duration of the NT (DNT) and number of syllables per second (NSS) were the duration parameters investigated.
  • CONCLUSION: Our findings show that L-dopa replacement therapy slightly improves the Fo range and the intensity of speech of Brazilian female PD patients.
  • They also indicate that therapies other than dopaminergic agents are warranted to treat speech abnormalities in PD.
  • [MeSH-major] Antiparkinson Agents / adverse effects. Levodopa / adverse effects. Parkinson Disease / drug therapy. Phonation / drug effects. Speech Acoustics. Speech Disorders / drug therapy. Speech Production Measurement

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14762605.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 46627O600J / Levodopa
  •  go-up   go-down


32. Zhang C, Liu F, Liu X, Chen D: Protective effect of N-acetylcysteine against BDE-209-induced neurotoxicity in primary cultured neonatal rat hippocampal neurons in vitro. Int J Dev Neurosci; 2010 Oct;28(6):521-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective effect of N-acetylcysteine against BDE-209-induced neurotoxicity in primary cultured neonatal rat hippocampal neurons in vitro.
  • It has been reported that BDE-209 induces developmental neurotoxicity in vivo.
  • BDE-209 was added to the cultures in increasing concentrations and co-cultured with NAC in order to assess the effect of NAC on BDE-209-induced neurotoxicity.
  • The difference between the NAC treatment groups and the BDE-209 groups without NAC was also significant (P<0.05), showing that BDE-209 increased apoptosis, the expression of p38 MAPK, the calcium ion concentration, and the ROS level and decreased cell viability.
  • The results suggested that NAC may be able to attenuate BDE-209-induced neurotoxicity.
  • [MeSH-major] Acetylcysteine / administration & dosage. Halogenated Diphenyl Ethers / toxicity. Hippocampus / drug effects. Hippocampus / physiopathology. Neurons / drug effects. Neurotoxicity Syndromes / drug therapy
  • [MeSH-minor] Animals. Animals, Newborn. Apoptosis / drug effects. Cell Survival / drug effects. Cells, Cultured. Dose-Response Relationship, Drug. Flame Retardants / toxicity. Neuroprotective Agents / administration & dosage. Neurotoxins / toxicity. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. DECABROMOBIPHENYL ETHER .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISDN. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20546880.001).
  • [ISSN] 1873-474X
  • [Journal-full-title] International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
  • [ISO-abbreviation] Int. J. Dev. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flame Retardants; 0 / Halogenated Diphenyl Ethers; 0 / Neuroprotective Agents; 0 / Neurotoxins; N80BQ29A0H / decabromobiphenyl ether; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


33. Moore JE, Millar BC, Yongmin X, Woodford N, Vincent S, Goldsmith CE, McClurg RB, Crowe M, Hone R, Murphy PG: A rapid molecular assay for the detection of antibiotic resistance determinants in causal agents of infective endocarditis. J Appl Microbiol; 2001 May;90(5):719-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapid molecular assay for the detection of antibiotic resistance determinants in causal agents of infective endocarditis.
  • AIMS: To develop and employ a PCR amplification system, directly from clinical specimens, for the rapid molecular detection of common antimicrobial resistance genes for streptococci, staphylococci and enterococci organisms causing infective endocarditis (IE).
  • CONCLUSION: This study presents a PCR amplification system for the detection of antibiotic resistance genes.
  • Detection of such genes may indicate susceptibility of the causal agents of IE to commonly prescribed antimicrobial agents.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Rapid detection of antibiotic resistant organisms may reduce the use of inappropriate antibiotic agents or enable the use of the most appropriate combinations of antibiotics, other than those that would normally be prescribed empirically for IE.
  • Detection of antibiotic resistance genes by molecular-based techniques, namely PCR, will allow more directed antibiotic therapy and may also provide opportunities for earlier identification of resistant organisms.
  • [MeSH-major] Drug Resistance, Microbial / genetics. Endocarditis, Bacterial / microbiology. Genes, Bacterial. Gram-Positive Cocci / drug effects. Polymerase Chain Reaction / methods
  • [MeSH-minor] Enterococcus / drug effects. Enterococcus / genetics. Enterococcus / isolation & purification. Heart Valves / microbiology. Humans. Methicillin / pharmacology. Methicillin Resistance / genetics. Penicillins / pharmacology. RNA, Ribosomal, 16S / analysis. Staphylococcus / drug effects. Staphylococcus / genetics. Staphylococcus / isolation & purification. Streptococcus / drug effects. Streptococcus / genetics. Streptococcus / isolation & purification


34. Ray DE, Fry JR: A reassessment of the neurotoxicity of pyrethroid insecticides. Pharmacol Ther; 2006 Jul;111(1):174-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reassessment of the neurotoxicity of pyrethroid insecticides.
  • Their acute toxicity is dominated by pharmacological actions upon the central nervous system (CNS), predominantly mediated by prolongation of the kinetics of voltage-gated sodium channels, although other mechanisms operate.
  • This review summarizes our present understanding of such actions and the pharmacological options to antagonize them.
  • The review also provides an overview of recent studies that suggest additional effects of pyrethroids: developmental neurotoxicity, the production of neuronal death, and action mediated via pyrethroid metabolites.
  • [MeSH-minor] Animals. Animals, Newborn. Biotransformation. Cell Death / drug effects. Central Nervous System / drug effects. Humans. Ion Channels / drug effects. Ion Channels / metabolism. Neurons / drug effects. Neurotoxicity Syndromes / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324748.001).
  • [ISSN] 0163-7258
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100165
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insecticides; 0 / Ion Channels; 0 / Pyrethrins
  • [Number-of-references] 197
  •  go-up   go-down


35. Roux FX, Nataf F: Cerebral oligodendrogliomas in adults and children. Current data and perspectives. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):410-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean survival is 13 years (154 +/- 20 months), with a mortality at 5 and 10 years of 60% +/- 9%, and a risk of recurrence of 54% +/- 9% at 5 years and 46.5% +/- 10.5% at 5 years.
  • The main differential diagnosis of grade A oligo is dysembryoplastic neuroepithelial tumors (DNT).
  • Inversely, thalamic locations, most often grade B, generally present with a motor deficit; complete removal can be achieved in only 15%.
  • The only efficient treatment is chemotherapy, requiring search for chemosensitivity (1p19q deletion, expression of MGMT gene, analysis by MR-spectroscopy and TEP).
  • [MeSH-minor] Adult. Child. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Diagnosis, Differential. Humans. Magnetic Resonance Spectroscopy. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292183.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng; fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Guizzetti M, Pathak S, Giordano G, Costa LG: Effect of organophosphorus insecticides and their metabolites on astroglial cell proliferation. Toxicology; 2005 Nov 15;215(3):182-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though little attention has been given to the possibility that glial cells may represent a target for the developmental neurotoxicity of organophosphorus (OP) insecticides, recent evidence, obtained in particular with chlorpyrifos (CP), suggests that developmental exposure to this compound may indeed target astrocytes.
  • In fetal rat astrocytes and astrocytoma cells maintained in serum, CP, DZ, P, CPO, DZO, and PO induced a concentration-dependent inhibition in [(3)H]thymidine incorporation with a very similar potency (IC(50) between 45 and 57 microM).
  • [MeSH-major] Astrocytes / drug effects. Astrocytoma / drug therapy. Cell Proliferation / drug effects. Insecticides / toxicity. Organophosphorus Compounds / toxicity
  • [MeSH-minor] Animals. Cell Line, Tumor. Chlorpyrifos / analogs & derivatives. Chlorpyrifos / toxicity. DNA / biosynthesis. DNA / drug effects. Diazinon / analogs & derivatives. Diazinon / toxicity. Dose-Response Relationship, Drug. Fetus / cytology. Inhibitory Concentration 50. Parathion / analogs & derivatives. Parathion / toxicity. Rats

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORPYRIFOS .
  • Hazardous Substances Data Bank. DIAZINON .
  • Hazardous Substances Data Bank. PARATHION .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102884.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES07033; United States / NIEHS NIH HHS / ES / ES09601
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Insecticides; 0 / Organophosphorus Compounds; 61G466064D / Parathion; 9007-49-2 / DNA; JCS58I644W / Chlorpyrifos; YUS1M1Q929 / Diazinon
  •  go-up   go-down


37. Ratel D, Boisseau S, Davidson SM, Ballester B, Mathieu J, Morange M, Adamski D, Berger F, Benabid AL, Wion D: The bacterial nucleoside N(6)-methyldeoxyadenosine induces the differentiation of mammalian tumor cells. Biochem Biophys Res Commun; 2001 Jul 20;285(3):800-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bacterial nucleoside N(6)-methyldeoxyadenosine induces the differentiation of mammalian tumor cells.
  • The possible biological effect of this nucleoside on eukaryotic cells has been studied on different tumor cell lines.
  • The biological effects of N(6)-methyldeoxyadenosine were not restricted to C6.9 glioma cells since differentiation was also observed on pheochromocytoma and teratocarcinoma cell lines and on dysembryoplastic neuroepithelial tumor cells.
  • Furthermore, the finding that a methylated nucleoside found in bacterial DNA induces a biological process might have implications in gene therapy approaches when plasmid DNAs are injected into humans.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation / drug effects. Deoxyadenosines / pharmacology. Glioma / metabolism. Muscle Proteins. Neoplasms, Neuroepithelial / metabolism. PC12 Cells / drug effects. Phosphoric Diester Hydrolases. Teratocarcinoma / metabolism
  • [MeSH-minor] 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase. 2',3'-Cyclic-Nucleotide Phosphodiesterases / biosynthesis. Animals. Antigens, Differentiation / biosynthesis. Blotting, Western. Cell Cycle / drug effects. Microfilament Proteins / metabolism. Rats. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11453663.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antineoplastic Agents; 0 / Deoxyadenosines; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / N(6)-methyldeoxyadenosine; 0 / Tagln protein, mouse; EC 3.1.4.- / 2',3'-Cyclic-Nucleotide Phosphodiesterases; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.37 / 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; EC 3.1.4.37 / CNP protein, human; EC 3.1.4.37 / Cnp protein, mouse; EC 3.1.4.37 / Cnp protein, rat
  •  go-up   go-down


38. Song JH, Kong DS, Seol HJ, Shin HJ: Transventricular Biopsy of Brain Tumor without Hydrocephalus Using Neuroendoscopy with Navigation. J Korean Neurosurg Soc; 2010 Jun;47(6):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transventricular Biopsy of Brain Tumor without Hydrocephalus Using Neuroendoscopy with Navigation.
  • OBJECTIVE: It is usually difficult to perform the neuroendoscopic procedure in patients without hydrocephalus due to difficulties with ventricular cannulation.
  • The procedure was indicated for verification of the histological diagnosis of the neoplasm, which was planned to be treated by chemotherapy and/or radiotherapy as the first line treatment, or establishment of the pathological diagnosis for further choice of the most appropriate treatment strategy.
  • The histopathologic diagnosis was established in all of 6 patients : 2 germinomas, 2 astrocytomas, 1 dysembryoplastic neuroepithelial tumor and 1 pineocytoma.
  • The tumor biopsy sites were pineal gland (n = 2), suprasellar area (n = 2), subcallosal area (n = 1) and thalamus (n = 1).
  • There were no operative complications related to the endoscopic procedure.
  • Image-guided neuroendoscopic procedure improved the accuracy of the endoscopic approach and minimized brain trauma.
  • The absence of ventriculomegaly in patients with brain tumor may not be served as a contraindication to endoscopic tumor biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1978 Mar-Apr;2(2):110-3 [732959.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1235-9 [19002372.001]
  • [Cites] Minim Invasive Neurosurg. 1995 Jun;38(2):79-84 [7583365.001]
  • [Cites] Acta Neurochir Suppl. 1994;61:76-8 [7771229.001]
  • [Cites] Childs Nerv Syst. 1994 Apr;10(3):162-6 [8044811.001]
  • [Cites] Pediatr Neurosurg. 1993 May-Jun;19(3):127-34 [8499325.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(1):12-20; discussion 20-1 [9059706.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Dec;40(4):139-43 [9477403.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):496-505 [9488304.001]
  • [Cites] Neurosurgery. 1998 Jun;42(6):1288-94; discussion 1294-6 [9632187.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;68(1-4 Pt 1):80-9 [9711700.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):1062-8 [9833841.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1103-9; discussion 1109-11 [10232544.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):245-53 [10930010.001]
  • [Cites] Pediatr Neurosurg. 2000 Sep;33(3):132-7 [11096360.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):72-9 [11147902.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):305-11 [11599445.001]
  • [Cites] Br J Neurosurg. 2002 Oct;16(5):465-70 [12498490.001]
  • [Cites] Neurosurgery. 2003 Mar;52(3):525-33; discussion 532-3 [12590676.001]
  • [Cites] Presse Med. 1963 May 18;71:1225-8 [13963492.001]
  • [Cites] Neurosurgery. 2005 Oct;57(4 Suppl):312-8; discussion 312-8 [16234680.001]
  • [Cites] Neurosurg Focus. 1999 Apr 15;6(4):e5 [16681359.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):251-6 [4694225.001]
  • (PMID = 20617084.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2899026
  • [Keywords] NOTNLM ; Navigation / Neuroendoscopy / Without hydrocephalus
  •  go-up   go-down


39. López JI, Pomposo-Gaztelu I: [Surgical pathology of epilepsy]. Rev Neurol; 2010 May 16;50(10):616-22
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The surgical treatment of refractory epilepsy represents a large step forward in the quality of life and survival of many patients, particularly for those whose pathology is located in the temporal lobe.
  • DEVELOPMENT: The causes of refractory epilepsy with a genuinely neurohistological foundation can be either malformative or neoplastic.
  • The former include cortical dysplasias and hippocampal sclerosis, while the latter involve the so-called glioneuronal tumours (dysembryoplastic neuroepithelial tumour, ganglioglioma) and some glial cell-related tumours.
  • Surgery applied to these processes cures epilepsy in a high percentage of cases that are resistant to pharmacological treatment.
  • [MeSH-minor] Brain Neoplasms / complications. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Ganglioglioma / complications. Ganglioglioma / pathology. Ganglioglioma / surgery. Humans. Neuroectodermal Tumors, Primitive / complications. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / surgery. Quality of Life. Temporal Lobe / pathology. Temporal Lobe / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473838.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 36
  •  go-up   go-down


40. Sarkar C, Sharma MC, Deb P, Singh VP, Chandra PS, Gupta A, Tripathi M, Bhatia M, Gaikwad S, Bal CS, Jain S: Neuropathological spectrum of lesions associated with intractable epilepsies: a 10-year experience with a series of 153 resections. Neurol India; 2006 Jun;54(2):144-50; discussion 150-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropathological spectrum of lesions associated with intractable epilepsies: a 10-year experience with a series of 153 resections.
  • BACKGROUND: Surgical management of intractable epilepsies is currently an established mode of therapy in various clinical settings.
  • In addition, 20.9% (32 cases) had dual lesions, majority of which included FCD with ganglioglioma (15 cases) or with dysembryoplastic neuroepithelial tumor (12 cases).
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Child. Child, Preschool. Diffuse Cerebral Sclerosis of Schilder / pathology. Diffuse Cerebral Sclerosis of Schilder / surgery. Drug Resistance. Encephalitis / pathology. Female. Humans. Infant. Male. Neurosurgical Procedures. Retrospective Studies. Temporal Lobe / surgery

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804257.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


41. Spivey A: Fat chance? A high-fat diet may offset the effects of developmental neurotoxicity. Environ Health Perspect; 2009 Jun;117(6):A257
Hazardous Substances Data Bank. PARATHION .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fat chance? A high-fat diet may offset the effects of developmental neurotoxicity.
  • [MeSH-major] Dietary Fats / pharmacology. Electrical Synapses / drug effects. Environmental Pollutants / toxicity. Neurotoxicity Syndromes / diet therapy

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Environ Health Perspect. 2009 Jun;117(6):916-22 [19590683.001]
  • (PMID = 19590672.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Comment; News
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Environmental Pollutants; 0 / Insecticides; 61G466064D / Parathion
  • [Other-IDs] NLM/ PMC2702435
  •  go-up   go-down


42. Moore JE, Maeda Y, Millar BC, Goldsmith CE, Coulter WA, Mason C, Elborn JS: Long-term antibiotic treatment of patients with cystic fibrosis: a commensal organism's view. Br J Biomed Sci; 2009;66(4):203-5
MedlinePlus Health Information. consumer health - Cystic Fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term antibiotic treatment of patients with cystic fibrosis: a commensal organism's view.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. Antibiotic Prophylaxis. Cystic Fibrosis / drug therapy. Drug Resistance, Microbial / genetics
  • [MeSH-minor] Adult. Child. Child, Preschool. Drug Therapy, Combination. Europe. Gene Transfer, Horizontal. Humans. Long-Term Care. Pseudomonas Infections / drug therapy. Pseudomonas aeruginosa. Respiratory System / microbiology. Respiratory Tract Infections / microbiology. Respiratory Tract Infections / prevention & control. Sputum / microbiology. Viridans Streptococci / drug effects


43. Brami-Zylberberg F, Beuvon F, Meder JF: [Case no 1. Neuroepithelial dysembryoplastic tumor]. J Radiol; 2003 Jan;84(1):78-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case no 1. Neuroepithelial dysembryoplastic tumor].
  • [Transliterated title] Cas no 1. Tumeur neuro-épithéliale dysembryoplasique.
  • [MeSH-major] Brain Neoplasms / diagnosis. Frontal Lobe. Neoplasms, Neuroepithelial / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adolescent. Biopsy. Diagnosis, Differential. Epilepsy / drug therapy. Epilepsy / etiology. Female. Humans. Magnetic Resonance Imaging. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12645516.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Moore JE, Shaw A, Millar BC, Martin SL, Murphy PG, Downey DG, Ennis M, Elborn JS: Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic fibrosis patients. Br J Biomed Sci; 2004;61(3):146-7
MedlinePlus Health Information. consumer health - Cystic Fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cystic Fibrosis / microbiology. Leukocyte Elastase / analysis. Serine Proteinase Inhibitors / therapeutic use. Sputum / microbiology. alpha 1-Antitrypsin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Bacterial Infections / complications. Bacterial Infections / drug therapy. Colony Count, Microbial / methods. Humans. Male. Middle Aged. Neutrophils / enzymology. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462261.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Serine Proteinase Inhibitors; 0 / alpha 1-Antitrypsin; EC 3.4.21.37 / Leukocyte Elastase
  •  go-up   go-down






Advertisement